Wednesday, January 31, 2018 1:36:34 PM
Intec Welcomes R. Michael Gendreau, M.D., Ph.D. as Chief Medical Officer
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/01/31/Intec-Welcomes-R-Michael-Gendreau-MD-PhD-as-Chief-Medical-Officer
JERUSALEM, Jan. 31, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) (TASE:NTEC), a clinical stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion Pill™platform technology, today announced it has named R. Michael Gendreau, M.D., Ph.D. to the position of Chief Medical Officer. Dr. Gendreau, a seasoned industry veteran, brings to Intec Pharma over 30 years of experience in the drug development and pharmaceutical industry.
"I am delighted to have Michael join our executive team. He is an extraordinarily talented individual who has extensive clinical trial experience and has helped obtain multiple FDA approvals," said Jeffrey A. Meckler, Chief Executive Officer of Intec Pharma. "His knowledge and experience will meaningfully impact and move forward our Accordion Pill clinical programs."
Michael added, "I am excited to join the Intec team. I look forward to contributing to the clinical development of the Accordion Pill technology platform and the completion of our Phase 3 AP-CD/LD program to bring this potentially game-changing therapy to Parkinson's patients around the world."
Dr. Gendreau joins Intec after having founded a consulting firm providing strategic advice on the design and management of clinical programs, strategic planning, and technology assessments for emerging pharmaceutical, diagnostic, and medical device companies. He has served on various scientific advisory boards, executive strategic planning boards, and Data Safety Monitoring Boards. Prior to his consulting career, Dr. Gendreau served as Chief Medical Officer at Cypress Bioscience, Inc., a clinical-stage biotech company developing therapies for central nervous system disorders. Additionally, he has served as Chief Medical Officer at other institutions including Battelle Memorial Institute. Dr. Gendreau received his B.S. in Chemistry from Ohio University, and earned his M.D./Ph.D. from The Ohio State University.
About Intec Pharma Ltd.
Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed for various indications including low back neuropathic pain and fibromyalgia.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company's control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission, and include the following: the company's ability to develop and commercialize its product candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of the company's clinical trials; including uncertainty regarding the Company's ability to enroll the required number of patients therein; the potential of adverse side effects, other safety risks, or legal prohibitions on the use of certain products in certain jurisdictions that could preclude the approval of the company's drug candidates; the availability of reimbursement from government authorities and health insurance companies for the company's products; the impact of product liability lawsuits; and the influence of extensive and costly government regulation.
Recent INDP News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 09/12/2024 08:45:11 PM
- Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses • GlobeNewswire Inc. • 09/05/2024 12:30:00 PM
- Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 12:00:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 08/22/2024 02:06:25 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/12/2024 12:16:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 12:01:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:00:28 PM
- Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/12/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 12:00:34 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/07/2024 09:28:25 PM
- Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/06/2024 09:23:56 PM
- Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit • GlobeNewswire Inc. • 06/11/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:30:38 PM
- Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference • GlobeNewswire Inc. • 06/04/2024 12:00:00 PM
- Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20 • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Indaptus Therapeutics to Present at the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 12:00:18 PM
- Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors • GlobeNewswire Inc. • 05/22/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 12:06:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 12:05:19 PM
- Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/08/2024 12:00:00 PM
- Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM